KEVIN O'SULLIVAN: Open Payments
NPI 1922492859 · TEXARKANA, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$967 in 32 payments from 16 companies in 2025. Trend: 2023 $1,274 · 2024 $910 · 2025 $967
Food & beverage: $967
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $176 |
| ABBVIE INC. | 3 | $156 |
| EVOKE PHARMA, INC. | 1 | $100 |
| Novo Nordisk Inc | 2 | $99 |
| Abbott Laboratories | 1 | $78 |
| Amgen Inc. | 4 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Phathom Pharmaceuticals, Inc. | 1 | $46 |
| PFIZER INC. | 2 | $40 |
| Exact Sciences Corporation | 2 | $33 |
Products named: FARXIGA, VRAYLAR, GIMOTI, Ozempic, FREESTYLE LIBRE 3, OTEZLA, CAPLYTA, VOQUEZNA.
Industry payments across AR — which companies pay providers there.
